-+ 0.00%
-+ 0.00%
-+ 0.00%

Leerink Partners Downgrades Aurinia Pharmaceuticals to Market Perform, Raises Price Target to $16

Benzinga·12/03/2025 13:33:55
语音播报
Leerink Partners analyst Joseph Schwartz downgrades Aurinia Pharmaceuticals (NASDAQ:AUPH) from Outperform to Market Perform and raises the price target from $15 to $16.